Submitted by gmonari on Tue, 04/03/2012 - 09:26
AMRI Signs Exclusive Option to License its Tubulin Inhibitor Program for Cancer
AMRI Signs Exclusive Option to License its Tubulin Inhibitor Program for Cancer --
Agreement Demonstrates AMRI’s Commitment to Value Creation from its Proprietary Portfolio of Compounds and Programs